Ceftriaxone (INN) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. In most cases, it is considered to be equivalent to cefotaxime in terms of safety and efficacy. Ceftriaxone sodium is marketed by Hoffman-La Roche under the trade name Rocephin, Rocetrax by Star Laboratories in Pakistan, as well as under various other names in several countries. Gepach International markets Ceftriaxone Injections under the brand name Cefatrin.
Ceftriaxone is often used (in combination, but not direct, with macrolide and/or aminoglycoside antibiotics) for the treatment of community-acquired or mild to moderate health care-associated pneumonia. It is also a choice drug for treatment of bacterial meningitis. In pediatrics, it is commonly used in febrile infants between 4 and 8 weeks of age who are admitted to the hospital to exclude sepsis. The dosage for acute ear infection in the very young is 50 mg IM, one dose daily up to three days. It has also been used in the treatment of Lyme disease, typhoid fever, and gonorrhea.
Intravenous dosages may be adjusted for body mass in younger patients and is administered every 12–24 hours, at a dose that depends on the type and severity of the infection.
CAS:73384-59-5
Molecular Formula:C18H18N8O7S3
Formula Weight:554.58
Specification:5g
No comments:
Post a Comment